Testing a new combination vaccine for flu and COVID-19

Plain-English translation of NCT07464314 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage study testing a new mRNA seasonal flu/COVID-19 combination vaccine in adults aged 65 to 85. Researchers want to understand whether this investigational mRNA seasonal flu/COVID-19 combination vaccine is safe and whether it helps your body build protection against both illnesses. The study will compare the new treatment with standard flu and COVID-19 vaccines that are already approved.

Right now, people need separate shots to protect against flu and COVID-19. This trial is exploring whether a single combination vaccine could work just as well, making vaccination simpler and easier for older adults.

Do you qualify?

You likely qualify if…

you are between 65 and 85 years old
you are generally healthy or have stable medical conditions
you have not had confirmed flu or COVID-19 in the recent past
you are able to follow study instructions and attend visits
you have not received certain vaccines in the weeks before the study

You likely don't qualify if…

you have a history of severe allergic reactions to flu vaccines, COVID-19 vaccines, or mRNA vaccines
you have a weakened immune system or certain heart conditions like myocarditis or pericarditis
you have had Guillain-Barré syndrome within the past 6 weeks of any vaccine
you have active cancer or a history of cancer that has not been in remission for at least 5 years
you have recently received another flu vaccine, COVID-19 vaccine, or mRNA vaccine

What participation looks like

You will receive a single shot of either the new combination vaccine at one of three dose levels, a standard flu vaccine, or a standard COVID-19 vaccine. Researchers will monitor you for side effects and collect blood samples at specific times to measure how well your body is building protection. The study is designed to be relatively brief, though you may need to return for follow-up visits and blood draws over several weeks.

AI-generated summary from trial data · Jul 2, 2026 · Not medical advice

Trial locations(12 sites)

United States

GSK Investigational Site, Anniston, Alabama

GSK Investigational Site, Little Rock, Arkansas

GSK Investigational Site, Fair Oaks, California

GSK Investigational Site, San Diego, California

GSK Investigational Site, Miami, Florida